Overview
MPLT market data
Price History
MPLT price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$18.56 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.75 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $9.10 – $40.43 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $519.1M · P/B 1.74.
Company News
8-K filing — MapLight Therapeutics, Inc. (MPLT)SEC EDGAR · Aug 13, 2026, 8:51 PM
MapLight Therapeutics Q2 EPS $(1.32) Beats $(1.35) EstimateBenzinga · Aug 13, 2026, 8:27 PM
MapLight Therapeutics Enters Securities Purchase Agreement For $150M Private Placement FinancingBenzinga · Aug 13, 2026, 1:12 PM
UBS Downgrades MapLight Therapeutics to Neutral, Lowers Price Target to $13Benzinga · Aug 10, 2026, 7:51 PM
Canaccord Genuity Maintains Buy on MapLight Therapeutics, Lowers Price Target to $24Benzinga · Jul 28, 2026, 1:10 PM
Morgan Stanley Downgrades MapLight Therapeutics to Equal-Weight, Lowers Price Target to $21Benzinga · Jul 28, 2026, 11:42 AM
HC Wainwright & Co. Maintains Buy on MapLight Therapeutics, Lowers Price Target to $26Benzinga · Jul 28, 2026, 10:19 AM
MapLight Therapeutics Stock Falls Despite Schizophrenia Drug Meeting Main Trial GoalBenzinga · Jul 27, 2026, 4:00 PM
MapLight Therapeutics shares are trading lower after the company announced the 2 ZEPHYR trial's 330/6 mg once-daily dose missed its primary endpoint.Benzinga · Jul 27, 2026, 1:00 PM
Maplight Therapeutics Says Phase 2 Zephyr Trial Of ML-007C-MA For Acute Exacerbation Of Schizophrenia Met Its Primary Endpoint, With 210/3 Mg Twice-Daily Dose, While 330/6 mg Once-daily Dose Missed Primary EndpointBenzinga · Jul 27, 2026, 11:07 AM